Division of General Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA.
J Womens Health (Larchmt). 2011 Apr;20(4):559-65. doi: 10.1089/jwh.2009.1915.
We aimed to assess the frequency of and experiences with use of bioidentical compounded hormone therapy (BCH) by women seen at an academic women's health clinic and menopause center.
Women seeking consultation for menopausal concerns from October 2005 to October 2006 were given a 19-item survey about their experiences with BCH and conventional hormone therapy (CHT).
Of 208 consecutive patients invited to take the survey, 184 consented and responded. Thirty-seven (20%) reported ever use of BCH, and 25 (14%) reported current use of BCH; 59% of BCH preparations used included androgens. Twenty-four of 31 BCH users (77%) believed BCH was safer than CHT. Menopausal symptoms leading to use of hormones were similar between BCH and CHT users. Symptom relief with use of CHT and BCH was similar, but relief of sexual symptoms was reported significantly more frequently by BCH than CHT users (78% vs 33%, p < 0.001).
Women lacked knowledge of safety concerns with BCH, reporting a belief that it was safer than CHT. Menopausal symptoms prompting BCH and CHT use were similar, but sexual symptoms were more frequently relieved by BCH, possibly because of the inclusion of androgens. Visits to health care providers for menopausal symptoms are ideal for physicians to educate women that in the absence of data to the contrary, BCH should be considered to have the same risks as CHT. Our findings of reported improvements in sexual symptoms among women using BCH merit further evaluation, with better identification of constituents in the products.
我们旨在评估在学术妇科诊所和更年期中心就诊的女性使用生物等效复合激素治疗（BCH）的频率和体验。
2005 年 10 月至 2006 年 10 月，对因更年期问题寻求咨询的女性进行了一项关于其使用 BCH 和常规激素治疗（CHT）经验的 19 项调查。
在 208 名受邀参加调查的连续患者中，184 名同意并做出了回应。37 名（20%）报告曾使用过 BCH，25 名（14%）报告目前正在使用 BCH；59%的 BCH 制剂包含雄激素。24 名 BCH 用户中的 24 名（77%）认为 BCH 比 CHT 更安全。导致使用激素的更年期症状在 BCH 和 CHT 用户之间相似。使用 CHT 和 BCH 缓解症状相似，但 BCH 用户报告的性症状缓解明显多于 CHT 用户（78%对 33%，p<0.001）。
女性对 BCH 的安全性问题缺乏了解，认为它比 CHT 更安全。促使 BCH 和 CHT 使用的更年期症状相似，但 BCH 更频繁地缓解性症状，可能是因为包含了雄激素。因更年期症状就诊是医生为女性提供教育的理想时机，告知她们在没有相反数据的情况下，应认为 BCH 与 CHT 具有相同的风险。我们发现使用 BCH 的女性报告的性症状改善值得进一步评估，需要更好地确定产品中的成分。
